No Fixed-Dose Combination Tablet Currently Available
There is currently no FDA-approved fixed-dose combination tablet that combines a GLP-1 receptor agonist and an SGLT2 inhibitor in a single pill. However, these two medication classes are frequently prescribed together as separate agents and are strongly recommended in clinical practice for patients with type 2 diabetes and cardiovascular or kidney disease.
Available Fixed-Dose Combinations (Different Drug Classes)
The only fixed-dose combinations involving GLP-1 receptor agonists that currently exist combine them with basal insulin, not SGLT2 inhibitors 1:
- Insulin glargine/lixisenatide (iGlarLixi): Maximum dose is 60 units insulin glargine with 20 mcg lixisenatide
- Insulin degludec/liraglutide (IDegLira): Maximum dose is 50 units insulin degludec with 1.8 mg liraglutide
These combinations are designed for patients requiring insulin intensification, not for the cardiorenal protection strategy that drives combined GLP-1 RA and SGLT2 inhibitor use.
Concomitant Use as Separate Agents is Recommended
Guidelines explicitly support using both drug classes together as separate medications when clinically indicated 2. The 2018 ACC Expert Consensus states: "it appears reasonable to use both an SGLT2 inhibitor and a GLP-1RA with demonstrated CV benefit concomitantly if clinically indicated" 2.
Evidence Supporting Combined Therapy
The most recent and compelling evidence comes from:
2026 meta-analysis of cohort studies 3: Combination therapy versus monotherapy showed:
- 44% reduction in MACE (RR 0.56,95% CI 0.43-0.71)
- 50% reduction in all-cause mortality (RR 0.50,95% CI 0.40-0.63)
- 74% reduction in cardiovascular mortality (RR 0.26,95% CI 0.16-0.43)
- 33% reduction in heart failure hospitalization (RR 0.67,95% CI 0.64-0.71)
- 52% reduction in kidney composite endpoints (RR 0.48,95% CI 0.32-0.73)
2023 post-hoc analysis 4: GLP-1 RAs reduced cardiovascular events independently of SGLT2 inhibitor use, with no interaction (P=0.95), suggesting additive benefits
Mechanistic Rationale for Separate Use
The drugs work through complementary, non-overlapping mechanisms 5:
GLP-1 receptor agonists:
- Anti-atherogenic effects
- Vascular protection
- Reduce ischemic stroke risk
- Improve endothelial function
SGLT2 inhibitors:
- Hemodynamic effects (reduce preload/afterload)
- Osmotic diuresis and natriuresis
- Shift myocardial substrate to ketones
- Marked reduction in heart failure hospitalization
- Superior kidney protection
Clinical Application
When to prescribe both separately:
Type 2 diabetes with established cardiovascular disease: Both classes reduce MACE; combination may provide additive benefit 6, 7
Heart failure with nonreduced ejection fraction (LVEF >40%): The 2025 Canadian guidelines list both SGLT2 inhibitors and GLP-1 RAs as evidence-based tier 1 therapies 6
Chronic kidney disease: SGLT2 inhibitors show superior kidney protection, but GLP-1 RAs (particularly semaglutide in FLOW trial) also reduce renal outcomes 8
High cardiovascular risk without established disease: Consider both for comprehensive risk reduction 7
Practical Considerations
- Cost: Using two separate branded medications significantly increases out-of-pocket expenses 2
- No antagonism: Despite opposite effects on glucagon, the DURATION-8 trial showed additive benefits on blood pressure and weight with combination therapy 2
- Safety: No increased risk of severe hypoglycemia, diabetic ketoacidosis, or genitourinary infections when used together 3
Bottom Line
While no single-pill combination exists, prescribing a GLP-1 receptor agonist and SGLT2 inhibitor as separate medications is evidence-based, guideline-supported, and increasingly common in clinical practice for patients with type 2 diabetes at high cardiorenal risk. The lack of a fixed-dose combination should not deter clinicians from using both drug classes when indicated, as their mechanisms are complementary and observational data suggest substantial additive cardiovascular and kidney benefits.